David Tanner, MD
Allergy & Immunology · Atlanta, GANPI 1396785218
Payments from drug & device makers
Across 448 payments — averaging $23.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$1K
- Sanofi$1K
- Takeda Pharmaceuticals U.S.A., Inc.$844
- CSL Behring$727
- Covis Pharma GmbH$691
- plus $5K from 31 others
What the payments were for
- Food & beverage$10,381100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 74 | $1,271 |
| AstraZeneca | 57 | $1,254 |
| Sanofi | 34 | $1,058 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $844 |
| CSL Behring | 27 | $727 |
| Covis Pharma GmbH | 31 | $691 |
| Biocryst US Sales Co., LLC | 23 | $576 |
| Octapharma USA, Inc. | 11 | $401 |
| Pharming Healthcare, Inc. | 16 | $383 |
| Regeneron Healthcare Solutions, Inc. | 12 | $333 |
| Kaleo, Inc. | 17 | $325 |
| Pfizer | 13 | $282 |
| Novartis | 8 | $265 |
| ARS Pharmaceuticals Operations, Inc. | 15 | $228 |
| Amgen | 12 | $222 |
| Optinose US, Inc. | 12 | $206 |
| Genentech USA, Inc. | 4 | $205 |
| Grifols USA, LLC | 8 | $187 |
| Teva Pharmaceuticals USA, Inc. | 10 | $165 |
| Boehringer Ingelheim | 6 | $124 |
| Lilly USA, LLC | 4 | $113 |
| Alk-abello, Inc | 4 | $80 |
| Jubilant Hollisterstier LLC | 1 | $57 |
| LEO Pharma Inc. | 2 | $50 |
| Organon | 2 | $45 |
| Kedrion Biopharma, Inc. | 2 | $44 |
| Cycle Pharmaceuticals Inc | 2 | $44 |
| Dermavant Sciences, Inc. | 1 | $26 |
| Greer Laboratories, Inc. | 1 | $25 |
| AbbVie | 1 | $22 |
| ADMA Biomanufacturing LLC | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Merck | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Biocryst Pharmaceuticals, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,392 in reported general payments places this provider in the 65th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 15 | $66,194 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $33,519 |
| Breo ElliptaFluticasone/Vilanterol | 57 | $32,335 |
| Advair HfaFluticasone Propion/Salmeterol | 26 | $18,168 |
| Arnuity ElliptaFluticasone Furoate | 46 | $16,048 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 57 | $11,788 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $6,203 |
| Epinephrine | 37 | $6,133 |
| DuleraMometasone/Formoterol | 14 | $5,773 |
| Wixela InhubFluticasone Propion/Salmeterol | 42 | $3,725 |
| AlvescoCiclesonide | 11 | $3,708 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 100 | $2,435 |
| Azelastine Hcl | 54 | $2,382 |
| AsmanexMometasone Furoate | 18 | $2,234 |
| Ipratropium Bromide | 44 | $1,998 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,271 | $81,902126 claims |
| MerckDulera, Asmanex | $20 | $8,00732 claims |
| AstraZenecaSymbicort | $1,254 | $6,20327 claims |
| Hikma Pharmaceuticals USAEpinephrine | $19 | $6,13337 claims |
| Covis Pharma GmbHAlvesco | $691 | $3,70811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Atlanta
- Deborah BirxAtlanta$470K
- Paul RabinowitzAtlanta$94K
- Santhosh Kumar Bangalore Vasantha KumarAtlanta$60K
- Gerald LeeAtlanta$52K
- Luqman SeiduAtlanta$46K
- Alan ReddingAtlanta$23K
- David ReddingAtlanta$22K
- Merin KalangaraAtlanta$19K
- Glen NadelAtlanta$12K
- Keith LenchnerAtlanta$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.